Background {#Sec1}
==========

Paclitaxel coated balloon (PCB) angioplasty has proven benefit in the treatment of bare-metal and drug-eluting in-stent restenosis (ISR) (Scheller et al. [@CR16], [@CR17], [@CR18]; Harbara et al. [@CR8]; Byrne et al. [@CR5]). The efficacy of PCB in treating small vessel de-novo lesions is also emerging with promising data so far (Ali et al. [@CR3]; Zeymer et al. [@CR24]). However, the data on PCB angioplasty specifically in acute coronary syndrome (ACS) is still lacking. Intravascular plaque rupture and thrombus formation in ACS cast doubt on the effectiveness of paclitaxel drug to be adequately delivered to the vessel wall. However, the increased risk of in-stent thrombosis and restenosis in small vessel PCI with stents (Akiyama et al. [@CR2]; Kasaoka et al. [@CR11]) has made PCB angioplasty, which leaves no intravascular metal a good alternative in theory. Therefore we utilise patients data from a prospective 'real world' registry to determine the feasibility of PCB angioplasty in acute coronary syndrome of small vessel de-novo lesions by means of major adverse cardiac event (MACE) and target lesion revascularisation (TLR) at 30-day and 9 months follow up.

Methods {#Sec2}
=======

Centres {#Sec3}
-------

Prospective patients enrolment was done in Germany (20 centres), Malaysia (4 centres), Singapore (3 centres), Italy (2 centres), France (1 centre), Finland (1 centre), Poland (1 centre), China (1 centre) and Iran (1 centre). The study was approved by the individual institutional review boards of the participating centres.

Materials {#Sec4}
---------

In this registry the paclitaxel coated percutaneous transluminal coronary angioplasty (PTCA) catheter based on the Paccocath Technology (SeQuent Please, B. Braun Melsungen AG) was used.

Inclusion and exclusion criteria {#Sec5}
--------------------------------

Patients ≥18 years of age with de novo small vessel lesions (2.0--2.75 mm diameter) and stable angina, documented ischemia (non-ACS) and acute coronary syndrome (ACS) were recruited for this registry. There were no patient exclusion criteria except those associated with contraindications for anti-platelet therapy.

Procedural approach {#Sec6}
-------------------

It was the purpose of this registry to treat de novo lesions with the PCB catheter only without additional stent implantations, according to the German Consensus Group recommendations (Kleber et al. [@CR12]). Predilatation with an uncoated balloon catheter according to the above mentioned recommendation was mandatory (Kleber et al. [@CR12]). In cases of severe dissections or unsatisfactory results post-PCB, the implantation of a BMS was recommended and left to the discretion of the interventionalist.

Vascular access was from the femoral or radial route with recommended diagnostic catheter of at least 5 French in diameter. Due to the 'all-comers' nature of this registry, efforts were made to not interfere with established national co-medication recommendations. Dual anti-platelet therapy (DAPT) with acetylsalicylic acid (aspirin) and an ADP receptor inhibitor (clopidogrel, prasugrel, or ticagrelor) was recommended, but at the discretion of the treating physician. An injectable anticoagulant was advised on the basis of local routines in the participating catheterisation laboratories.

Postprocedural medication {#Sec7}
-------------------------

An ADP receptor antagonist (clopidogrel 75 mg/day, prasugrel 10 mg/day or ticagrelor 180 mg/day) was recommended for either 1, 3--6 or 12 months together with aspirin 100--325 mg/day at the discretion of the treating physician.

Definitions {#Sec8}
-----------

MACE included TLR, myocardial revascularisation, and death of cardiac or unknown origin. MI was diagnosed with corresponding ECG changes and/or cardiac enzyme elevations according to each institution's routine diagnostic algorithms.

End points {#Sec9}
----------

Clinically driven TLR (either by re-do PCI or CABG) at 9 months post procedure was the primary end point. Secondary end points were procedural success rate, definite acute/sub-acute vessel thrombosis rates based on the Academic Research Consortium (ARC) criteria (Cutlip et al. [@CR7]) and major adverse cardiac events (MACE) as the composite of TLR, cardiac death, and myocardial infarction.

Data collection {#Sec10}
---------------

Baseline and clinical follow-up data were collected through a web based data acquisition system between June 2011 and December 2012. Follow up data were typically collected during routine visits with the treating physician. National principal investigators (one per country) were responsible for the accuracy of their datasets. Source data verification was done when the routinely performed web based plausibility checks indicated discrepancies.

Statistical analysis {#Sec11}
--------------------

Categorical variables were evaluated with the χ^2^ test. Continuous variables were typically compared with the unpaired two-tailed Student's t test. In parameters with Gaussian distributions, samples were described using the mean and the SD. SPSS V.20.0 (IBM, Munich, Germany) was used for all analyses at a significance level α of 0.05.

Results {#Sec12}
=======

Patients demographics and presentation {#Sec13}
--------------------------------------

A total of 471 PCB angioplasties were performed in 447 patients of which 113 (25 %) were ACS (STEMI/NSTEMI). A small proportion of patients (7.2 %) had bail-out BMS stenting. Patients baseline characteristics are shown in Table [1](#Tab1){ref-type="table"}. All clinical characteristics were similar in the ACS and non-ACS groups except for hyperlipidaemia and previous PCI where the non-ACS group had higher rates for both.Table 1Patient demographics and presentationsVariableAll patientsnon ACSACSp valueNumber of patients447334113--Number of lesions471365106--Age (years)66.1 ± 10.966.2 ± 10.265.9 ± 12.90.761Male gender324 (72.5 %)247 (72.2 %)77 (73.3 %)0.824Diabetes164 (36.7 %)128 (37.4 %)36 (34.3 %)0.559Hypertension360 (80.5 %)281 (82.2 %)79 (75.2 %)0.117Hyperlipidemia308 (68.9 %)244 (71.3 %)64 (61.0 %)0.044History of smoking169 (37.8 %)128 (37.4 %)41 (39.0 %)0.765Renal insufficiency44 (9.8 %)32 (9.4 %)12 (11.4 %)0.533Prior PCI238 (53.2 %)193 (56.4 %)45 (42.9 %)0.015Prior CABG44 (9.8 %)34 (9.9 %)10 (9.5 %)0.900Atrial fibrillation41 (9.2 %)31 (9.1 %)10 (9.5 %)0.887Age group ≥75 year113 (25.3 %)84 (24.6 %)29 (27.6 %)0.528STEMI41 (9.2 %)0 (0.0 %)41 (39.0 %)--NSTEMI64 (14.3 %)0 (0.0 %)64 (61.0 %)--*PCI* percutaneous coronary intervention, *CABG* coronary artery bypass graft, *STEMI* ST-elevation myocardial infarction, *NSTEMI* non-ST elevation myocardial infarction

Lesion characteristics and procedural data {#Sec14}
------------------------------------------

The mean vessel diameter for the ACS and non-ACS group were 2.15 ± 0.36 and 2.14 ± 0.35 respectively. Similar mean lesion length of around 15.5 mm was recorded in both groups. The LAD was the most common target vessel for both the ACS and non-ACS group. The distribution of coronary arteries treated were similar for both groups. In terms of lesion characteristics, the ACS group had more acute total occlusion (15.1 vs 7.4 %, p = 0.015) and higher thrombus burden rate (13.2 vs 0.3 %, p = 0.001). The degree of stenosis is also higher in the ACS group (88.5 vs 84.5 %, p = 0.001). Apart from the above, both ACS and non-ACS group have no significant difference in coronary artery complexity. Additional stenting was required in 9.3 % ACS and 6.5 % non-ACS, p = 0.308. Reasons for additional stenting were target lesion related dissection (57.6 %) or non-target lesion stenosis (41.2 %).

Periprocedure anti-platelet therapy {#Sec15}
-----------------------------------

All patients were on aspirin. Clopidogrel was the most common second anti-platelet drug followed by prasugrel, ticagrelor and ticlopidine. A small minority of patients were on single antiplatelet aspirin (5.7 % ACS and 4.7 % non-ACS). No significant difference in the ACS and non-ACS groups in terms of periprocedural anti-platelet therapy (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}).Table 2Lesion characteristics and procedural data in ACS and non-ACS patientsVariableAll patientsNon ACSACSp valueNumber of lesions471353118--Target vessel LAD193 (41.0 %)154 (42.2 %)39 (36.8 %)0.128 LCX126 (26.8 %)91 (24.9 %)35 (33.0 %) RCA94 (20.0 %)69 (18.9 %)25 (23.6 %) Ramus intermedius19 (4.0 %)17 (4.7 %)2 (1.9 %) Other39 (8.9 %)34 (9.3 %)5 (4.7 %)Lesion characteristics Total occlusion43 (9.1 %)27 (7.4 %)16 (15.1 %)0.015 Chronic total occlusion16 (3.4 %)13 (3.6 %)3 (2.8 %)0.714 Thrombus burden15 (3.2 %)1 (0.3 %)14 (13.2 %)\<0.001 Diffuse vessel disease200 (57.5 %)156 (42.7 %)44 (41.5 %)0.822 Calcification112 (23.8 %)83 (22.7 %)29 (27.4 %)0.325 Vein graft9 (1.9 %)8 (2.2 %)1 (0.9 %)0.409 Ostial lesion48 (10.2 %)35 (9.6 %)13 (12.3 %)0.423 Bifurcation lesion45 (9.6 %)35 (9.6 %)10 (9.4 %)0.962 Severe tortuosity45 (9.6 %)32 (8.8 %)13 (12.3 %)0.281 AHA/ACC type B2/C lesion182 (38.6 %)133 (36.4 %)49 (46.2 %)0.068 Reference diameter (mm)2.14 ± 0.352.14 ± 0.352.15 ± 0.360.973 Lesion length15.5 ± 7.015.5 ± 7.315.6 ± 5.90.926 Degree of stenosis (%)85.3 ± 11.284.5 ± 11.488.5 ± 10.20.001Procedural data Predilation device diameter (mm)2.02 ± 0.252.01 ± 0.242.04 ± 0.290.303 Predilatation device length (mm)15.6 ± 4.515.7 ± 4.615.5 ± 4.30.655 Predilatation device pressure (atm)11.8 ± 3.111.8 ± 3.211.7 ± 3.10.941 DEBs used478371107-- DEBs per patient1.07 ± 0.291.08 ± 0.321.03 ± 0.170.114 DEB diameter (mm)2.33 ± 0.312.32 ± 0.302.37 ± 0.320.138 DEB length (mm)19.2 ± 4.519.2 ± 4.518.8 ± 4.30.425 DEB inflation pressure (atm)11.0 ± 3.410.9 ± 2.811.3 ± 4.90.352 DEB inflation time (s)48.5 ± 15.948.5 ± 16.048.6 ± 15.60.982 Additional stent34 (7.2 %)24 (6.5 %)10 (9.3 %)0.308 Overall technical success per used device (n = 478)473 (99.0 %)368 (99.2 %)105 (98.1 %)0.342*LAD* left anterior descending artery, *LCX* left circumflex artery, *RCA* right coronary artery, *AHA/ACC* American Heart Association/American College of Cardiology, *DEB* drug eluting balloonTable 3Peri-procedural antiplatelet therapy in ACS and non-ACS patientsVariableAll patientsNon ACSACSp valueAspirin447 (100 %)334 (100 %)113 (100 %)-- Clopidogrel364 (81.4 %)277 (81.0 %)87 (82.9 %)0.792 Prasugrel41 (9.2 %)32 (9.4 %)9 (8.6 %) Ticagrelor8 (1.8 %)6 (1.8 %)2 (1.9 %) Ticlopidine4 (0.9 %)4 (1.2 %)0 (0.0 %)Aspirin + vitamin K antagonists9 (2.0 %)8 (2.3 %)1 (1.0 %)Aspirin only21 (4.7 %)15 (4.4 %)6 (5.7 %)GP IIb/IIIa inhibitors10 (2.2 %)8 (2.3 %)2 (1.9 %)0.792*GP IIb/IIIA* glycoprotein IIb/IIIaTable 4Duration of dual antiplatelet therapy during follow-up in ACS and non-ACS patientsVariableAll patientsNon ACSACSp valueNumber of patients447334113--4 weeks aspirin 100 mg + clopidogrel267 (59.7 %)207 (60.5 %)60 (57.1 %)0.3853 months aspirin 100 mg + clopidogrel5 (1.2 %)5 (1.5 %)0 (0.0 %)6--12 months aspirin 100 mg + clopidogrel68 (15.2 %)52 (15.2 %)16 (15.2 %)12 months aspirin 100 mg + clopidogrel70 (15.7 %)47 (13.7 %)23 (21.9 %)Aspirin 100 mg + clopidogrel life long2 (0.4 %)2 (0.6 %)0 (0.0 %)12 months aspirin 100 mg + prasugrel3 (0.7 %)2 (0.6 %)1 (1.0 %)12 months aspirin 100 mg + ticagrelor3 (0.7 %)2 (0.6 %)1 (1.0 %)Unknown29 (6.5 %)24 (7.0 %)5 (4.8 %)

Duration of dual anti-platelet therapy (DAPT) during follow up {#Sec16}
--------------------------------------------------------------

More than half of the patients had 4 weeks of aspirin/clopidogrel (57.1 % ACS, 60.5 % non-ACS). No significant difference between the ACS and non-ACS groups with regards to the duration and types of DAPT during follow up.

Clinical outcome {#Sec17}
----------------

Table [5](#Tab5){ref-type="table"} illustrates the clinical outcome of the patients. The primary end-point of 9 months TLR were 1.2 % ACS versus 4.3 % non-ACS (p = 0.180). Overall, the MACE rate at 9 months was 4.7 % for the entire registry. MACE rates were 0 % at 30-day and 3.6 % at 9 months in the ACS group. The rates were lower as compared to the non-ACS group, but were not significantly different. No cases of target lesion/vessel or non-target vessel thrombosis reported in the ACS group.Table 5Clinical outcomes in patient populations in ACS and non-ACS patientsVariableAll patientsNon ACSACSp valueNumber of patients447334113--Patients with clinical follow-up384 (85.9 %)301 (90.3 %)83 (73.5 %)0.021Follow-up time (months)9.4 ± 1.79.5 ± 1.79.4 ± 1.60.87530-day MACE1 (0.3 %)1 (0.3 %)0 (0.0 %)0.59930-day TLR1 (0.3 %)1 (0.3 %)0 (0.0 %)0.59930-day MI1 (0.3 %)1 (0.3 %)0 (0.0 %)0.59930-day cardiac death0 (0.0 %)0 (0.0 %)0 (0.0 %)--9-month MACE18 (4.7 %)15 (5.0 %)3 (3.6 %)0.6019-month TLR14 (3.6 %)13 (4.3 %)1 (1.2 %)0.1809-month MI7 (1.8 %)4 (1.3 %)3 (3.6 %)0.1689-month cardiac death0 (0.0 %)0 (0.0 %)0 (0.0 %)--9-month vessel thrombosis3 (0.8 %)3 (1.1 %)0 (0.0 %)0.356 Target lesion0 (0.0 %)0 (0.0 %)0 (0.0 %)-- Target vessel2 (0.5 %)2 (0.7 %)0 (0.0 %)0.457 Non-target vessel1 (0.3 %)1 (0.3 %)0 (0.0 %)0.599*MACE* major adverse cardiac events, *TLR* target lesion revascularisation, *MI* myocardial infarction

Discussion {#Sec18}
==========

The definition of small vessel from the literature varies. For our registry, we took the cut-off point of 2.75 mm or less as small vessel. From coronary revascularisation point of view, small vessel PCIs make up a significant portion constituting to about 35--45 % of all PCIs (Zeymer and Scheller [@CR23]). PCI with stenting in small vessels remains challenging as the outcome is poorer compared to PCI of larger vessels. Small vessels have less tolerance to neointimal proliferation post stent implantation (Hausleiter et al. [@CR9]; Agostoni et al. [@CR1]). The risk of ISR in small vessels even with the introduction of DES stents is still considered significant (Meier et al. [@CR14]; Togni et al. [@CR19]). This is in addition to the already known complication of stent thrombosis.

PCB angioplasty in small vessels was first reported in 2010 which showed a TLR rate of 4.9 % in PCB only patients (n = 73) with reference diameter of 2.36 ± 0.18 mm and lesion lengths of 11.3 ± 4.3 mm (Unverdoben et al. [@CR20]). After the initial failure of PICCOLETTO study trial (Cortese et al. [@CR6]) to show a non-inferiority of PCB versus DES, came a larger randomised trial comparing PCB and DES in small vessel de novo lesions (BELLO study) (Latib et al. [@CR13]). BELLO study comprising 182 patients, showed superiority of PCB over TAXUS stents in terms of late lumen loss (LLL) and similar angiographic restenosis, target lesion revascularisation and MACE rates at 6 months. Patients from the BELLO study were then followed up for 2 years and showed better TLR rates (compared to PES TAXUS) at 6 months (4.4 vs 7.6 %), 1 year (6.7 vs 12.1 %) and 2 years (6.8 vs 12.1 %) (Naganuma et al. [@CR15]).

Stent implantation is considered the standard and well established treatment for ACS (Windecker et al. [@CR21]) to improve clinical outcome. However PCI in ACS in small vessels is not spared from the issue of high ISR rate and stent thrombosis. Evidence of PCB specifically in ACS is still sparse. Besic et al. ([@CR4]) reported a significantly lower LLL of PCB + BMS combination compared to BMS alone at 6 months but no significant difference in MACE and binary LLL and ISR were noted.

There is now rather convincing data on the efficacy and safety of PCB in small vessels de novo lesions in general (Zeymer et al. [@CR24]). However its use in ACS in particular is still unclear. Ho et al. ([@CR10]) reported MACE rate of 4.5 % in PCB primary angioplasty of STEMI at 30-day follow up. Our study shows the outcome of PCB in ACS and non-ACS is comparably similar in small vessel de novo lesions. MACE rate at 30-days and 9-months follow up showed a better trend in ACS than the non-ACS group. MACE at 30 days is 0.3 % non-ACS versus 0 % ACS and 9-months MACE is 5.0 % non-ACS versus 3.6 % ACS. In comparison to other small vessel de novo lesion studies, TLR at 9-months follow up was reported as 3.6 % (PCB only) and 4.0 % (PCB + BMS) (Zeymer et al. [@CR24]) and 1 % (PCB only) and 2.4 % (PCB + BMS) (Wohrle et al. [@CR22]). The mean vessel diameter difference for the two above studies might explain the lower rate of TLR.

Conclusion {#Sec19}
==========

The use of PCB in ACS of small vessel de novo lesion is associated with a low TLR/MACE rate comparable to small vessel PCB angioplasty in general. This suggests PCB angioplasty in ACS is a feasible alternative to stent implantation in ACS.

Study limitation {#Sec20}
================

Since the purpose of this observational study was the documentation of PCB angioplasty in the clinical routine, event underreporting may have occured. In this context, the procedural details could have been specified in more detail as well. For instance in case of thrombus burden the type of the aspiration device would have been highly desirable. Furthermore, in the case of PCB angioplasty one needs to point out that the learning curve to treat small lesions with PCB only requires positive clinical feedback of each investigator. This entails a learning curve to accept angiographically 'unpleasing' results for the benefit of having no implant in a small vessel. However, due to the level of each investigator's experience a selection bias could not be ruled out in this assessment.
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